Market cap
$5,705 Mln
Revenue (TTM)
$5,203 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
16.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
356,536,358
6 Years Aggregate
CFO
$3,285.00 Mln
EBITDA
$4,526.00 Mln
Net Profit
$928.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bausch + Lomb Corp (BLCO)
| -6.9 | -2.6 | -3.0 | 46.0 | -3.1 | -- | -- |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
|---|---|---|
|
Bausch + Lomb Corp (BLCO)
| -5.4 | 10.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 |
|
BSE Sensex
| 9.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bausch + Lomb Corp (BLCO)
|
15.9 | 5,704.6 | 5,203.0 | -219.0 | 4.6 | -3.5 | -- | 0.9 |
| 7.2 | 262.0 | 16.4 | 42.3 | -260.2 | 55.9 | -- | 3.7 | |
| 3.7 | 162.3 | 285.3 | -10.7 | -0.9 | -9.2 | -- | 1.6 | |
| 9.2 | 326.4 | 270.3 | 14.9 | 8.6 | 10.9 | 23 | 2.6 |
Shareholding Pattern
View DetailsAbout Bausch + Lomb Corp (BLCO)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision... Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 Read more
-
Executive VP & CFO
Mr. Osama A. Eldessouky
-
CEO & Chairman
Mr. Brenton L. Saunders J.D.
-
Headquarters
Vaughan, ON
-
Website
FAQs for Bausch + Lomb Corp (BLCO)
What is the current share price of Bausch + Lomb Corp (BLCO) Today?
The share price of Bausch + Lomb Corp (BLCO) is $15.91 (NYSE) as of 07-May-2026 16:10 EDT. Bausch + Lomb Corp (BLCO) has given a return of -3.13% in the last 3 years.
What is the current PB & PE ratio of Bausch + Lomb Corp (BLCO)?
Since, TTM earnings of Bausch + Lomb Corp (BLCO) is negative, P/E ratio is not available.
The P/B ratio of Bausch + Lomb Corp (BLCO) is 0.91 times as on 07-May-2026, a 66 discount to its peers’ median range of 2.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-16.79
|
0.94
|
|
2024
|
-20.04
|
0.98
|
|
2023
|
-23.02
|
0.87
|
|
2022
|
904.75
|
0.77
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Bausch + Lomb Corp (BLCO)?
The 52-week high and low of Bausch + Lomb Corp (BLCO) are Rs 18.92 and Rs 10.85 as of 08-May-2026.
What is the market cap of Bausch + Lomb Corp (BLCO)?
Bausch + Lomb Corp (BLCO) has a market capitalisation of $ 5,705 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bausch + Lomb Corp (BLCO)?
Before investing in Bausch + Lomb Corp (BLCO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.